

Dan T Vogl, Msce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3801166/publications.pdf>

Version: 2024-02-01

77
papers

6,241
citations

126907

33
h-index

82547

72
g-index

78
all docs

78
docs citations

78
times ranked

8251
citing authors

#	ARTICLE	IF	CITATIONS
1	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015, 21, 914-921.	30.7	728
2	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2019, 129, 2210-2221.	8.2	513
3	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1040-1047.	27.0	511
4	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
5	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	10.7	263
6	Post-traumatic stress disorder in cancer: a review. , 1999, 8, 521-537.		210
7	Carfilzomib-Associated Cardiovascular Adverse Events. <i>JAMA Oncology</i> , 2018, 4, e174519.	7.1	196
8	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	1.6	184
9	Symptom Prevalence, Characteristics, and Distress in AIDS Outpatients. <i>Journal of Pain and Symptom Management</i> , 1999, 18, 253-262.	1.2	183
10	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. <i>JAMA Internal Medicine</i> , 2021, 181, 195.	5.1	168
11	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	1.6	163
12	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. <i>Lancet Haematology</i> , the, 2015, 2, e408-e416.	4.6	158
13	Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. <i>Blood</i> , 2011, 117, 788-797.	1.4	148
14	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	1.6	140
15	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	140
16	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 2812-2815.	5.2	133
17	Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1355-1365.	7.0	116
18	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98

#	ARTICLE	IF	CITATIONS
19	A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 6732-6739.	7.0	97
20	Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells. <i>Clinical Cancer Research</i> , 2009, 15, 4499-4507.	7.0	91
21	A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. <i>Kidney International</i> , 2018, 94, 199-205.	5.2	90
22	Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 335-345.	0.4	88
23	A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1530-1538.	4.1	81
24	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. <i>Blood</i> , 2011, 118, 1979-1988.	1.4	77
25	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
26	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
27	Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2008, 83, 747-749.	4.1	63
28	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8506-8506.	1.6	63
29	Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. <i>Cancer Letters</i> , 2016, 371, 117-124.	7.2	59
30	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
31	Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1765-1774.	2.0	53
32	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1872-1879.	1.3	50
33	Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. <i>Blood</i> , 2011, 117, 63-71.	1.4	41
34	Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases. <i>Leukemia and Lymphoma</i> , 2007, 48, 885-891.	1.3	40
35	Medical management update: Multiple myeloma. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2007, 103, 599-609.	1.4	36
36	RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. <i>Leukemia</i> , 2019, 33, 2006-2021.	7.2	36

#	ARTICLE	IF	CITATIONS
37	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , 2019, 3, 2487-2490.	5.2	35
38	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
39	Successful Treatment of T-cell Post-Transplant Lymphoproliferative Disorder with the Retinoid Analog Bexarotene. <i>American Journal of Transplantation</i> , 2005, 5, 2070-2073.	4.7	32
40	A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 5619-5625.	7.0	32
41	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , 2016, 128, 5702-5702.	1.4	31
42	Scleromyxedema and dermatomyositis syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. <i>American Journal of Hematology</i> , 2011, 86, 893-896.	4.1	29
43	Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 536-540.	0.4	28
44	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016, 128, 974-974.	1.4	28
45	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 147, 531-534.	2.5	27
46	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	1.4	21
47	Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. <i>Leukemia and Lymphoma</i> , 2005, 46, 1313-1320.	1.3	20
48	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1886-1886.	1.4	19
49	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> , 2022, 12, 27.	6.2	19
50	Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2017, 102, e261-e265.	3.5	17
51	Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. <i>American Journal of Hematology</i> , 2007, 82, 1071-1075.	4.1	15
52	Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2020, 189, e126-e130.	2.5	13
53	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	1.4	13
54	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1863-1863.	1.4	13

#	ARTICLE	IF	CITATIONS
55	The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: a pilot study. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2011, 111, 326-332.	1.4	12
56	Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2321-2330.	4.1	12
57	The evolving role of plerixafor in hematopoietic progenitor cell mobilization. <i>Transfusion</i> , 2013, 53, 2314-2326.	1.6	12
58	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	1.4	12
59	Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2119-2119.	1.4	12
60	Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking. <i>Clinical Chemistry</i> , 2021, 68, 230-239.	3.2	11
61	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	11
62	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	1.4	9
63	Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. <i>Medical Oncology</i> , 2008, 25, 299-302.	2.5	8
64	Crystal-storing histiocytosis in plasma cell myeloma. <i>American Journal of Hematology</i> , 2010, 85, 444-445.	4.1	8
65	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	2.6	8
66	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. <i>British Journal of Haematology</i> , 2021, 193, 851-855.	2.5	6
67	Post-traumatic stress disorder in cancer: a review. <i>Psycho-Oncology</i> , 1999, 8, 521-537.	2.3	5
68	Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. <i>Blood</i> , 2019, 134, 1854-1854.	1.4	5
69	Untangling immunotactoid glomerulopathy in the MGRS era. <i>Kidney International</i> , 2021, 99, 303-305.	5.2	3
70	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019, 134, 1872-1872.	1.4	3
71	The Rationale for Combined Proteasome and Autophagy Inhibition in Multiple Myeloma Established Using Novel Translational Platforms. <i>Blood</i> , 2008, 112, 2755-2755.	1.4	3
72	A unique window of opportunity for practical reform of cancer clinical trials. <i>Cancer</i> , 2021, 127, 2855-2860.	4.1	2

#	ARTICLE	IF	CITATIONS
73	A Phase I Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 5188-5188.	1.4	2
74	Hypertriglyceridemia presenting as "pink blood" and elevated hemoglobin level. <i>American Journal of Hematology</i> , 2008, 83, 253-253.	4.1	0
75	Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. <i>Journal of Clinical Oncology</i> , 2021, , JCO2101754.	1.6	0
76	Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases.. <i>Blood</i> , 2005, 106, 1507-1507.	1.4	0
77	Detection of the Malignant B Cell Clone in Multiple Myeloma Via High Throughput Sequencing Is Robust to Significant Levels of Somatic Hypermutation. <i>Blood</i> , 2014, 124, 3413-3413.	1.4	0